{"id":480,"date":"2016-09-22T23:05:32","date_gmt":"2016-09-22T20:05:32","guid":{"rendered":"https:\/\/www.sightsciences.com\/ous\/?p=480"},"modified":"2016-09-22T23:05:32","modified_gmt":"2016-09-22T20:05:32","slug":"sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial","status":"publish","type":"post","link":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/","title":{"rendered":"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial"},"content":{"rendered":"<p>Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world\u2019s first clinical trial comparing ab interno canaloplasty with selective laser trabeculoplasty. Study will evaluate the safety and effectiveness of an ab interno procedure for patients with primary open angle glaucoma who do not have co-existing cataracts \u2013 the majority of the glaucoma patient population.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world\u2019s first clinical trial comparing ab interno canaloplasty with selective laser trabeculoplasty. Study will evaluate the safety and effectiveness of an ab interno procedure for patients with primary open angle [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6],"tags":[],"class_list":["post-480","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.1 (Yoast SEO v27.1.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial - International<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial\" \/>\n<meta property=\"og:description\" content=\"Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world\u2019s first clinical trial comparing ab interno canaloplasty with selective laser trabeculoplasty. Study will evaluate the safety and effectiveness of an ab interno procedure for patients with primary open angle [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"International\" \/>\n<meta property=\"article:published_time\" content=\"2016-09-22T20:05:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sightsciences.com\/ous\/wp-content\/uploads\/sites\/3\/2024\/04\/SISC_RTS_Logo_Primary_RGB_P1-1200.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin-dev\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin-dev\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/\"},\"author\":{\"name\":\"admin-dev\",\"@id\":\"https:\/\/www.sightsciences.com\/ous\/#\/schema\/person\/88f84507b2364aa1168168756f61f091\"},\"headline\":\"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial\",\"datePublished\":\"2016-09-22T20:05:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/\"},\"wordCount\":91,\"commentCount\":0,\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/\",\"url\":\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/\",\"name\":\"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial - International\",\"isPartOf\":{\"@id\":\"https:\/\/www.sightsciences.com\/ous\/#website\"},\"datePublished\":\"2016-09-22T20:05:32+00:00\",\"author\":{\"@id\":\"https:\/\/www.sightsciences.com\/ous\/#\/schema\/person\/88f84507b2364aa1168168756f61f091\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sightsciences.com\/ous\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sightsciences.com\/ous\/#website\",\"url\":\"https:\/\/www.sightsciences.com\/ous\/\",\"name\":\"International\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sightsciences.com\/ous\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sightsciences.com\/ous\/#\/schema\/person\/88f84507b2364aa1168168756f61f091\",\"name\":\"admin-dev\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sightsciences.com\/ous\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g\",\"caption\":\"admin-dev\"},\"url\":\"https:\/\/www.sightsciences.com\/ous\/author\/admin-dev\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial - International","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/","og_locale":"en_US","og_type":"article","og_title":"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial","og_description":"Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world\u2019s first clinical trial comparing ab interno canaloplasty with selective laser trabeculoplasty. Study will evaluate the safety and effectiveness of an ab interno procedure for patients with primary open angle [&hellip;]","og_url":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/","og_site_name":"International","article_published_time":"2016-09-22T20:05:32+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.sightsciences.com\/ous\/wp-content\/uploads\/sites\/3\/2024\/04\/SISC_RTS_Logo_Primary_RGB_P1-1200.png","type":"image\/png"}],"author":"admin-dev","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin-dev"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/#article","isPartOf":{"@id":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/"},"author":{"name":"admin-dev","@id":"https:\/\/www.sightsciences.com\/ous\/#\/schema\/person\/88f84507b2364aa1168168756f61f091"},"headline":"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial","datePublished":"2016-09-22T20:05:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/"},"wordCount":91,"commentCount":0,"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/","url":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/","name":"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial - International","isPartOf":{"@id":"https:\/\/www.sightsciences.com\/ous\/#website"},"datePublished":"2016-09-22T20:05:32+00:00","author":{"@id":"https:\/\/www.sightsciences.com\/ous\/#\/schema\/person\/88f84507b2364aa1168168756f61f091"},"breadcrumb":{"@id":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sightsciences.com\/ous\/sight-sciences-receives-full-investigational-device-exemption-ide-approval-from-the-us-fda-to-initiate-the-visco360-versus-slt-glaucoma-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sightsciences.com\/ous\/"},{"@type":"ListItem","position":2,"name":"Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO\u2122360 Versus SLT Glaucoma Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.sightsciences.com\/ous\/#website","url":"https:\/\/www.sightsciences.com\/ous\/","name":"International","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sightsciences.com\/ous\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sightsciences.com\/ous\/#\/schema\/person\/88f84507b2364aa1168168756f61f091","name":"admin-dev","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sightsciences.com\/ous\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7b9b8f03f53de455547cff48e35299ac8abad46d269b304aaf6215427c968767?s=96&d=mm&r=g","caption":"admin-dev"},"url":"https:\/\/www.sightsciences.com\/ous\/author\/admin-dev\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/posts\/480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/comments?post=480"}],"version-history":[{"count":0,"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/posts\/480\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/media?parent=480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/categories?post=480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sightsciences.com\/ous\/wp-json\/wp\/v2\/tags?post=480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}